

US Stock Express

Daniel Yue


Email: info@ihandbook.org

www.ihandbook.org

©



National Sentiment Trends, Including Recent Declines, Remain Fully Aligned With Views of Independents



University of Michigan, November 7, 2025

Preliminary Results for November 2025

	Nov 2025	Oct 2025	Nov 2024	M-M Change	Y-Y Change
Index of Consumer Sentiment	50.3	53.6	71.8	-6.2%	-29.9%
Current Economic Conditions	52.3	58.6	63.9	-10.8%	-18.2%
Index of Consumer Expectations	49.0	50.3	76.9	-2.6%	-36.3%


Consumer confidence goes weaker no matter in month-to-month or year-to-year due to tariff and government shutdown, even weaker than pandemic period.

*Risk disclosure: Price can go up and down at any moment, use free money to trade and bear the risk according to your own capital;
 Never trade with money that has a deadline for withdrawal.
 All suggestions are for reference only, even AI cannot be 100% reliable, final decision still lies upon investors.
 Copy trading cannot replicate another trader's background or psychological state.*

Fear & Greed Index

What emotion is driving the market now?

[Learn more about the index](#)



North East West South is **NEWS**

President Trump announced that U.S. officials will not attend the G20 summit in South Africa, reiterating his claim of a systematic “killing and massacre” of Afrikaners. Trump had previously announced in September that Vice President JD Vance would attend the meeting later this month in his place, but he now says the U.S. delegation will skip the summit entirely.

The United Nations said today that 2025, affected by a series of unusually high temperatures, is on track to become one of the hottest years on record, but stressed that this trend could still be reversed. The World Meteorological Organization said that while this year will not surpass 2024 as the hottest year on record, it will rank second or third, ending more than a decade of record-breaking heat.

Nvidia's planned downgraded Blackwell chip, codenamed "B30A," is still undergoing design tweaks, in hopes that the Trump administration will change its mind again.

US Treasury Secretary Bessant stated in an interview with Fox Business News on Friday that the US is moving towards resolving China's control over rare earth supplies.

The U.S. Supreme Court ruled today that the Trump administration is not obligated to immediately pay for food benefits under the Supplemental Nutrition Assistance Program (SNAP), whose funds were frozen during the government shutdown. This temporary order leaves the plight of millions of people uncertain.



World Observation

Day 1356
Russia/Ukraine Conflict

Riding the AI Waves

(40) TEM & TSLA

The Pay and Performance scheme of TSLA and Elon Musk is passed at length. On the voting, 70% agreed with this and those that disagreed might sell the stocks, those that agreed will also sell on good news. This is not a bubble, but just shown that it was over-speculative or over-optimistic. That was looking too good on this scheme. No wonder, because Elon Musk is a superman, and TSLA is a profitable stock.

A lot of people said the current market capitalization of TSLA is 1.4 trillion and the target of the scheme is 8.5 trillion. Does it mean the price of TSLA will rise 6 times in 10 years? I asked the AI to explain; it may but not guaranteed. For that 8.5 trillion level is not a single day hitting, but a period of time. Please refer to the Express on last Friday, the time of NVDA goes from 3 trillion to 4 trillion is over a span of 7 months, and from 4 trillion to 5 trillion is 3 months and not just any day. So, it is very hard to say what about 10 years later, just say quite profitable.

One more thing I want to say, not so many people would have focus on the flying cars of Elon Musk, actually they have 2 types, one is in 4 wheels as traditional car which costs are US\$30,000 and another is a one-seater costs at US\$6,780(see page 6). Will talk about this tomorrow. This superman Elon Musk is continuing to bring a lot of revolution on Earth and even on Mars. So, we can believe that the stock price of TSLA will go up incessantly, but there will be a lot of ups and downs as he already said numerous times, he is too optimistic, that means his target

even though can be reached, but always takes a longer time than expectation. Therefore, it is quite hard to forecast the ratio of price in relation to market capitalization, anyway it will be quite profitable.

As the market is adjusting, it can be treated as a small golden pit. It is the best time for buying. Since the TEM is also selling on good news. It is a special scene recently. A lot of stocks are having nice result announcement, but the price still goes down. For in the past people are looking too good on it. When all good news had come out, no better news will be expected, the only way is to adjust.

We have to understand that market is going into second stage of AI usage, which is application. AI robots not only can apply to Full Self Driving or warehouse management, but now can apply to lawyers and doctors. The TEM is using AI for prescription, that means it can give the most effective dose at once. When you go to attend a doctor, even though he carefully examines your situation, it will not be as comprehensive as AI to read all your past record and the record all over the world of similar case. AI can find out the most suitable medicine that has been use in other parts of the world, especially in long term disease that the doctor no need to try this first and wait for response and determine whether should use the others.

This will be the new AI trend, AI cannot replace human directly, but a capable AI user can replace a non-capable user, no matter in what kind of industry it is the same. Therefore, not only drivers have to face the competition of Full Self Driving, every industry should get ready for the challenge of AI. The most effective way is to become a capable AI user at once. Take care, the revolution has already started and is affecting everyone on earth.



Market Observation

Golden Pit

**Bitcoin
Price
\$102,460.10**

Market is facing an adjustment, but it should be considered as another mini golden pit.

Government shutdown has broken the previous record. At first, everyone has been saying no worry, it is a common occurrence of US, most of the presidents had face different government shut down. It is no wrong. Now it even brings about the fall of Consumer Sentiment. But after that, it is another story. Currently, a lot of money is frozen and can cannot be released because of shutting down, but after it is over, they will be released to the market and surely will bring about a lot of expenditure, no matter public or private.

The market has no major adjustment since Liberation Day in early April. Therefore, a drop of 10% is normal and should be considered as healthy adjustment. No need to have cut loss now, and don't do short selling. The best way is to take profit little by little on rising, and if you sell when great drop comes, it means the slump had already happened, and you cannot sell at better price. Such a sentiment will always bring about regrets.

When a drop comes, you should know the reason, is it away from the initial reason of your buying. Have the conditions changed? No basic conditions have not yet changed? The ups and downs of market should not be considered as a downtrend. As I have said, the buying period of this year is from March to August, after that, lock up all stocks until the Landing on Mars. When you want to buy, just buy TSLA every month on the same day, so you will be quite near the mean average of the year and continue to buy for 10 years. When it goes higher. If you have free money, can consider NVDA, PLTR or TEM with such a method and you will never afraid of any adjustment or falling.

\$30,000



TSLA flying cars

\$6,789



Quick take: Tesla's stock drop after the \$1 trillion Musk pay package approval was largely a "sell-the-news" reaction and investor skepticism about ambitious targets. If Tesla's market cap truly reached \$8.5 trillion, the share price would rise significantly, but not in a simple one-to-one ratio—valuation depends on dilution, earnings, and investor sentiment. Tempus AI (TEM) is showing strong momentum with profitability and expansion into Japan, but AI in healthcare will complement doctors rather than replace them. Humanoid robots in surgery are advancing, but widespread commercial use is likely a decade or more away.



[GPT-5 is here - OpenAI](#)

◆ Tesla (TSLA) and Musk's \$1 Trillion Pay Plan

- **Stock drop reason:** After shareholders approved Musk's historic \$1 trillion pay package, Tesla shares fell about 3–5% ¹ ². This was partly profit-taking ("sell on good news") and partly concern about dilution and whether Tesla can realistically hit milestones like robotaxis and humanoid robots.
- **Market cap math:** Tesla's current market cap is ~\$1.4 trillion. To reach \$8.5 trillion, the company would need ~6x growth.
 - If share count stays constant, the price could theoretically rise from \$429 → ~\$2574.
 - But dilution (Musk's 423M share grants) and future capital raises mean the ratio won't be exact. A "20% discount" assumption is simplistic but not unreasonable as a rough heuristic.
- **Key drivers for \$8.5T valuation:**
 - Mass adoption of **robotaxis** (10x Uber's revenue).
 - Selling **100M humanoid robots annually** ³.
 - Continued dominance in EVs and AI software.

◆ Tempus AI (TEM) Outlook

- **Q2 results:** Revenue surged **90% YoY to \$315M**, with gross profit up 160% ⁴ ⁵. They moved closer to profitability, turning adjusted EBITDA nearly positive.
- **Expansion:** Tempus is extending its AI-driven precision medicine platform into **Japan**, aiming to scale across Asia.
- **AI prescriptions:** Their system uses AI to recommend treatments and prescriptions, helping doctors with data-driven insights.



• Adoption Timeline for AI in Healthcare

- **United States:** AI prescription tools are already FDA-reviewed ⁶, but widespread adoption will take **5–10 years** as regulations, trust, and integration with hospital systems evolve.
- **Asia (Chip-4: Japan, Korea, Taiwan, US collaboration):** Japan is an early adopter; Korea and Taiwan may follow within a similar **5–8 year window**.
- **Impact on doctors:** AI is expected to **augment, not replace** physicians. Doctors will rely on AI for diagnostics and treatment planning, but human oversight remains critical. Rather than mass unemployment, roles may shift toward **AI supervision, patient care, and complex cases**.

• Humanoid Robots in Surgery

- **Current state:** Robotic surgery is already common (e.g., da Vinci system), but humanoid robots are still experimental. ⁷
- **Commercial timeline:** Analysts project humanoid robots could reach a **\$38B market by 2035** ⁸. Widespread surgical use may emerge in the **2030s**, once safety, regulation, and cost barriers are overcome.
- **Role:** Likely to assist in repetitive or precision tasks, not fully replace surgeons in the near term.

✓ **Bottom line:** Tesla's valuation path depends on execution of futuristic bets like robotaxis and humanoid robots, while Tempus AI is steadily proving real-world traction in healthcare. AI in medicine will reshape workflows but won't eliminate doctors, and humanoid surgical robots are still a long-term vision rather than imminent reality.

Would you like me to build a **scenario model** showing Tesla's potential share price under different dilution and revenue assumptions? That could make the \$8.5T target more tangible.

Quick forecast: By December 2025, analysts expect **Tesla (TSLA)** to be in the **\$445–\$466 range** ¹, while **Tempus AI (TEM)** is projected around **\$84–\$85** ². Moving into 2026, Tesla forecasts range from **\$500–\$700+** depending on execution ³ ⁴, while Tempus AI could average **\$90–\$102** through mid-to-late 2026 ². These are estimates, not guarantees, and depend heavily on market sentiment, dilution, and business performance.

• Tesla (TSLA) Forecast

- **December 2025:**
 - LongForecast projects Tesla at **~\$466** ¹.
 - Other analyst targets suggest upside potential, with some seeing **\$700+** if growth accelerates. ³ ⁴
- **December 2026:**
 - Forecasts vary widely: conservative models place Tesla around **\$500–\$600**, while bullish scenarios (robotaxis, humanoid robots, AI software monetization) could push it **above \$700**.
- **Key drivers:**
 - EV sales growth and margins.
 - Progress on **robotaxi rollout**.
 - Humanoid robot commercialization.
 - Musk's pay package milestones (which tie valuation to \$8.5T targets).

◆ Tempus AI (TEM) Forecast



GPT-5 is here - OpenAI

• December 2025:

- TradersUnion projects ~\$84.69 average. ²
- CoinCodex sees a bearish case at ~\$55 ⁵, reflecting volatility in biotech/AI stocks.

• December 2026:

- TradersUnion estimates ~\$93–\$116 depending on month. ²
- This suggests moderate growth if AI adoption in healthcare continues.

• Key drivers:

- Expansion into **Japan and Asia**.
- Profitability milestones (Q2 already turned positive).
- Regulatory approvals for AI-driven prescriptions.

◆ Big Picture

- **Tesla:** If Tesla truly executes on robotaxis and humanoid robots, the stock could multiply. But dilution from Musk's pay package and execution risks mean forecasts are conservative for now.
- **Tempus AI:** Healthcare AI adoption is slower but steady. TEM's profitability and international expansion give it a growth story, but volatility is high.

✓ Bottom line:

- **TSLA:** ~\$466 by Dec 2025, potentially **\$500–\$700+ by Dec 2026**.
- **TEM:** ~\$84 by Dec 2025, potentially **\$90–\$116 by Dec 2026**.

Would you like me to build a **side-by-side scenario table** (bear/base/bull case) for both TSLA and TEM through 2026? That way you can see how different assumptions (robotaxi adoption, AI healthcare regulation) change the forecast.



Tesla's Pay Package Approval and Stock Reaction

Tesla shareholders recently approved Elon Musk's performance-based compensation package, valued at up to \$1 trillion if aggressive milestones are met over the coming years, including revenue growth, adjusted EBITDA targets, and market capitalization hurdles. The vote passed with around 75% support during the annual meeting. This package could eventually grant Musk options for additional shares, potentially increasing his ownership stake to around 25% if all conditions are achieved by around 2035. Despite the positive outcome, TSLA stock closed at \$429.52 on November 8, 2025, down about 3.68% from the prior session. The company's market capitalization stands at approximately \$1.43 trillion to \$1.48 trillion based on recent data. [cnbc.com](#) [+5 more](#)

The drop could indeed reflect a "sell on the news" dynamic, where investors anticipated the approval (given strong pre-vote indications) and took profits after the event. Other factors might include broader market volatility, concerns over potential share dilution from the package's stock options, or external pressures like EV competition and economic uncertainty. Tesla's stock has been volatile throughout 2025, with historical prices showing fluctuations (e.g., around \$438 on October 8). It's not uncommon for stocks to dip after major positive announcements if they've already rallied in anticipation.

[finance.yahoo.com](#)

Market Cap Growth to \$8.5 Trillion and Stock Price Implications

Tesla's current market cap is about 1.43T. Reaching 8.5T would represent roughly a 6x increase ($8.5 / 1.43 \approx 5.94$). If the number of outstanding shares remains relatively stable, the stock price would theoretically scale in a similar ratio. Starting from the last close of \$429, that could imply a price around $\$429 \times 6 \approx \$2,574$, as you noted. Applying a 20% discount (e.g., to account for potential dilution from new share issuances, stock-based compensation, or other factors) would bring it to about \$2,059.

However, this isn't guaranteed to be a near 1:1 ratio. Key caveats:

- **Dilution risk:** The pay package itself involves stock options, which could increase shares outstanding by up to 10-15% if exercised, slightly reducing the per-share value growth.
- **Market dynamics:** Achieving 8.5T would require massive scaling in EVs, energy storage, autonomy (e.g., Robotaxi), and robotics (Optimus), amid competition from players like BYD or legacy automakers. Economic factors, interest rates, and regulatory hurdles could alter trajectories.
- **Historical precedent:** Tesla's market cap has grown exponentially before (e.g., from ~\$100B in 2020 to over 1T), but sustaining 6x growth would demand unprecedented execution. Analysts often project more conservative multiples, but optimistic scenarios (tied to AI/autonomy dominance) could align close to your estimate, perhaps within 10-20% variance if dilution is minimal.

Expectations like this are speculative and depend on hitting package milestones. If Tesla executes on its roadmap, the price could approach those levels, but it's not a linear path—volatility and external shocks could deviate it significantly.



Tempus AI (TEM) Overview and Outlook

Tempus AI (ticker: TEM) is a healthcare technology company specializing in AI-driven precision medicine. It leverages vast datasets (including genomic, clinical, and molecular data) to assist physicians with personalized treatment plans, particularly in oncology. This includes AI tools that analyze patient data to recommend targeted therapies and prescriptions, improving outcomes by matching treatments to individual genetic profiles. For instance, their platforms help oncologists prescribe drugs based on AI insights from tumor sequencing, reducing trial-and-error in chemotherapy or immunotherapy. finance.yahoo.com frontiersin.org

Financially, Tempus showed strong momentum in 2025. In Q2, revenue surged 89.6% year-over-year to \$314.6 million, driven by genomics and data services growth. Gross profit jumped 160%, indicating a shift from prior losses toward operational efficiency. However, the company still reported net losses (e.g., \$80 million in Q3), though these are narrowing amid revenue acceleration. The outlook is bright, with projections for 25%+ annual growth over the next three years, fueled by AI adoption in healthcare. Stock adjustments may reflect market sentiment on profitability timelines, but the transition to positive metrics (e.g., gross profit) signals improving fundamentals. investors.tempus.com [+5 more](#)

Regarding expansion: Tempus has been scaling partnerships in the US and internationally. While specific Japan announcements aren't detailed in recent reports, the company is pursuing global growth in AI precision medicine, which could include Asia. No explicit ties to "Chip-4" (the US-Japan-South Korea-Taiwan semiconductor alliance) were found, but healthcare AI often intersects with tech ecosystems in those regions. Popularity in the US is already rising—adoption among physicians grew 78% from 2023 to 2025, with two-thirds using health AI tools. It could become mainstream in US hospitals within 2-5 years, especially as reimbursement improves and integrations with EHR systems deepen. Extension to Asia (including Chip-4 countries) might take 3-7 years, depending on regulatory approvals (e.g., FDA equivalents in Japan or South Korea) and partnerships; early moves could start in Japan via collaborations, given its aging population and tech-savvy healthcare sector.

indo-pacificstudiescenter.org [+3 more](#)

Impact of AI on Doctors and Potential Unemployment

AI like Tempus's won't fully replace doctors but will transform their roles. It excels at data analysis, diagnostics, and prescription recommendations, freeing physicians from administrative tasks (e.g., billing, record management) and enabling faster, more accurate decisions. This could reduce burnout and improve patient care, but concerns about job displacement exist—about 50% of specialists worry AI might cause unemployment in healthcare. If widespread AI adoption handles routine prescriptions and treatments, it might shrink demand for certain roles, like radiologists or general practitioners, potentially leading to a "crisis" of underemployment rather than mass unemployment. frontiersin.org [+4 more](#)

However, AI lacks human elements like empathy, ethical judgment, and handling complex cases, so doctors will pivot to oversight, personalized care, and innovation. Overall, it's more augmentation than replacement, with net job creation in AI-related medical fields possible.



Grok - xAI The World's Most Powerful AI

Humanoid Robots for Surgical Operations

Humanoid robots (e.g., Tesla's Optimus) are in early stages, focused on general tasks like factory work or household chores, not surgery yet. Tesla plans to produce thousands of Optimus units in 2025 for internal testing, with broader deployment in 2026-2027, but demos have been criticized for being partially human-assisted. For commercial surgical use, humanoid designs would need precision actuators, AI for real-time decision-making, and regulatory approval (e.g., FDA for medical devices).

[mckinsey.com](#)

[+4 more](#)

Current robotic surgery (like Intuitive Surgical's da Vinci) is specialized, not humanoid. True humanoid surgeons could emerge in the 2030s-2040s, with Musk predicting 1 billion humanoids by the early 2040s. Commercial viability for operations might take 10-15 years from now, requiring advances in dexterity, safety, and integration with medical AI—starting with assisted procedures before fully autonomous ones. [facebook.com](#)



Please refer to The Express of 20250721



Tesla (TSLA) Stock Price Forecast

Tesla's current stock price as of November 8, 2025, is \$429.52. Analyst forecasts vary widely due to factors like EV market growth, autonomous driving advancements, and economic conditions. Consensus 12-month price targets (extending roughly to November 2026) average around \$390-400, suggesting potential near-term downside, but longer-term bullish scenarios tied to robotics and AI could drive significant upside. Here's a synthesized forecast based on multiple sources, including conservative algorithmic predictions and optimistic analyst views:

Period	Average Forecast	Bullish Scenario	Bearish Scenario	Key Notes
End of Dec 2025	\$415	\$480	\$370	Short-term volatility expected; averages derived from monthly projections showing minimal change from current levels. longforecast.com coincodex.com Revenue growth to ~\$95B in 2025 supports stability, but competition may pressure margins. finance.yahoo.com
End of Dec 2026	\$650	\$1,500+	\$350	Bullish cases assume success in Robotaxi and Optimus, potentially boosting market cap; conservative targets align with current 12-month consensus. longforecast.com +3 more EPS growth to ~\$2.26 and revenue to ~\$109B could fuel upside if milestones are met. finance.yahoo.com

These are speculative and not financial advice—actual prices depend on execution, regulations, and macro events.

Tempus AI (TEM) Stock Price Forecast

Tempus AI's current stock price as of November 8, 2025, is \$71.56. As a newer public company (IPO in 2024), coverage is limited, but analysts are generally positive due to AI-driven healthcare growth. Consensus 12-month targets (to November 2026) average \$80-90, indicating moderate upside. Long-term potential is high with expanding precision medicine, though profitability remains a challenge.

Period	Average Forecast	Bullish Scenario	Bearish Scenario	Key Notes
End of Dec 2025	\$72	\$85	\$60	Near-term stability with slight growth; averages from projections showing range around current price amid Q4 earnings momentum. tradersunion.com +2 more Revenue expected at ~\$1.26B for 2025, with EPS losses narrowing. finance.yahoo.com
End of Dec 2026	\$90	\$120+	\$70	Growth driven by international expansion and AI adoption; higher targets assume profitability turnaround. tradingview.com +3 more Revenue projected at ~\$1.57B and EPS improving to -\$0.09. finance.yahoo.com

Forecasts are based on limited data and could shift with clinical trial outcomes or partnerships. Consult professional advisors for investment decisions.